Ann Dermatol.  2013 Nov;25(4):496-497. 10.5021/ad.2013.25.4.496.

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab

• Ohshima Y
• Kinoshita
• Akita Y
• Tamada Y
• Watanabe D

• KMID: 2265070
• DOI: http://doi.org/10.5021/ad.2013.25.4.496

Abstract

No abstract available.

MeSH Terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Arthritis, Psoriatic*
Adalimumab
Infliximab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized

Figure

• 

  Fig. 1 (A~C) Course of treatment of the dorsal rash. (D~F) Course of treatment of the nail lesions. (A, D) Prior to adalimumab treatment. (B, E) After 6 weeks. (C, F) After 12 weeks. Prior to the adalimumab treatment, hyperkeratotic erythematous plaques had been observed on the trunk and extremities, but the scales had disappeared after 12 weeks, and only faint erythema was apparent. The psoriasis area severity index (PASI) score was 14.2, but decreased to 3.2 after 6 weeks and to 1.6 after 12 weeks. The nail lesions had shown onycholysis and pitting of the nail plate. It became flat, and the turbidity disappeared after 12 weeks.

Reference

1. Ohtsuki M, Terui T, Ozawa A, Morita A, Sano S, Takahashi H, et al. The guideline and safety manual for use of anti-TNFα agents in psoriasis. Jpn J Dermatol. 2010; 120:163–171.

2. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008; 58:106–115.

3. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. EXPRESS study investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005; 366:1367–1374.

4. Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007; 57:269–275.

5. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002; 46:1451–1459.